Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Huang, X
  • Ning, YM
  • Mulquin, M
  • Madan, RA
  • Gulley, JL
  • Kluetz, PG
  • Adelberg, D
  • Arlen, PM
  • Parnes, HL
  • Adesunloye, B
  • Steinberg, SM
  • Wright, JJ
  • Trepel, JB
  • Chen, C
  • Bassim, Carol Walker
  • Apolo, AB
  • Figg, WD
  • Dahut, WL

publication date

  • May 20, 2011